title: [Long-term efficacy of CAMSBDH-ALL chemotherapy protocol for the treatment of childhood acute lymphoblastic leukemia].
abstract: OBJECTIVE
  To study the long-term efficacy of CAMSBDH-ALL chemotherapy protocol for the treatment of childhood acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  Three hundred and eighteen children who were newly diagnosed with ALL between January 1999 and December 2007 were enrolled in this study. Among the 318 children, 83 children who hospitalized before December 2002 were treated with CAMSBDH-ALL99 protocol, including 48 patients of standard risk and 35 patients of high risk. The patients (n=235; 131 in standard risk and 104 in high risk) who hospitalized after December 2002 were treated with CAMSBDH-ALL03 protocol. Patients in the CAMSBDH-ALL99 protocol group were treated with conventional chemotherapy. CAMSBDH-ALL03 protocol was modified based on the CAMSBDH-ALL99 protocol.
  
  
  RESULTS
  The long-term overall survival (OS) and event-free-survival (EFS) in the CAMSBDH-ALL03 group was significantly higher than in the CAMSBDH-ALL99 (P&lt;0.01). The long-term OS and EFS of standard risk and high risk patients in the CAMSBDH-ALL03 protocol group were significantly higher than in the CAMSBDH-ALL99 protocol group (P&lt;0.01). The CAMSBDH-ALL03 protocol group showed a significantly lower recurrence rate (28.9%) than in the CAMSBDH-ALL99 protocol group (50.6%) (P&lt;0.05). The mortality rate in the CAMSBDH-ALL03 protocol group was 28.5% vs 56.6% in the CAMSBDH-ALL99 protocol group (P&lt;0.05).
  
  
  CONCLUSIONS
  The therapeutic effect of the CAMSBDH-ALL03 protocol is supior to the CAMSBDH-ALL99 protocol group for childhood ALL, with a higher long-term survival rate.
authors.affiliation: Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College, Tianjin 300020, Chian. xfzhu1981@126.com.
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Chen
authors.forename: Yao
authors.initials: Y
authors.lastname: Zou
authors.forename: Yu-Mei
authors.initials: YM
authors.lastname: Chen
authors.forename: Wen-Yu
authors.initials: WY
authors.lastname: Yang
authors.forename: Shu-Chun
authors.initials: SC
authors.lastname: Wang
authors.forename: Ye
authors.initials: Y
authors.lastname: Guo
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Ruan
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Liu
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: Tian-Feng
authors.initials: TF
authors.lastname: Liu
authors.forename: Jia-Yuan
authors.initials: JY
authors.lastname: Zhang
authors.forename: Ben-Quan
authors.initials: BQ
authors.lastname: Qi
authors.forename: Li-Xian
authors.initials: LX
authors.lastname: Chang
authors.forename: Xiao-Fan
authors.initials: XF
authors.lastname: Zhu
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence